Heather King, MD
Surgical Oncology · Austin, TXNPI 1992952659
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Leica Microsystems Inc. at 26.8% of the total. Reporting peaked in 2022 at $1,437 and has fallen 89.7% since, to $148 in 2025.
Across 32 payments — averaging $163.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Leica Microsystems Inc.$1K
- Axogen$979
- Stryker$785
- Endomagnetics Ltd$686
- Impedimed, Inc.$500
- Dilon Technologies, Inc.$264
- plus $611 from 5 others
What the payments were for
- Consulting fees$87217%
- Speaking & faculty fees$93618%
- Travel & lodging$3557%
- Food & beverage$2,97257%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Leica Microsystems Inc. | 4 | $1,404 |
| Axogen | 9 | $979 |
| Stryker | 5 | $785 |
| Endomagnetics Ltd | 1 | $686 |
| Impedimed, Inc. | 1 | $500 |
| Dilon Technologies, Inc. | 4 | $264 |
| Sirius Medical Systems | 2 | $237 |
| Davol Inc. | 1 | $157 |
| Lilly USA, LLC | 3 | $106 |
| Tactile Systems Technology Inc | 1 | $96 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,231 in reported general payments places this provider in the 70th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $139 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Austin
- Kimberly BrownAustin$20K
- Shaun McKenzieAustin$8K
- Allison DipasqualeDallas$272K
- Merrick RossHouston$216K
- John HardawayShenandoah$164K
- Steven CurleyTyler$162K
- Suhail SharifFort Worth$137K
- Alfredo Santillan GomezSan Antonio$125K
- Kelly HuntHouston$104K
- Adam YoppDallas$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.